A pilot retrospective cohort study published in The Cureus Journal of Medical Science has set out to identify the clinical indicators that should raise suspicion of dapsone-induced methemoglobinemia in dermatology outpatients — a rare but potentially serious hematologic adverse effect of one of dermatology's oldest systemic drugs.

Dapsone remains a workhorse agent in dermatology, used across a range of indications from dermatitis herpetiformis to inflammatory and neutrophilic disorders. Yet its use carries a well-recognized toxicity profile, and methemoglobinemia sits among the most clinically significant hazards. The new study asks a practical question: which presenting signs and measurable values in an outpatient dermatology population most reliably flag the condition before it progresses?

What did the study design involve?

The investigators conducted a retrospective cohort analysis — a pilot effort — focused on dermatology outpatients receiving dapsone. Retrospective designs of this type cannot establish causation the way a randomized trial can, but they are well suited to surfacing patterns in real-world prescribing populations, where monitoring is heterogeneous and adverse events often first appear as subtle deviations from baseline.

By reviewing records rather than prospectively enrolling patients, the authors captured data from routine dermatology practice rather than a controlled trial environment. That framing matters for interpretation: the findings describe how methemoglobinemia announces itself in the wild, not under protocol-specified surveillance.

Why does methemoglobinemia matter on dapsone?

Dapsone-induced methemoglobinemia arises when the drug and its hydroxylamine metabolite oxidize hemoglobin's iron from the ferrous to the ferric state, impairing oxygen release at the tissue level. The clinical consequence is functional anemia: patients may complain of fatigue, dyspnea, headache or cyanosis that does not improve with supplemental oxygen, while pulse oximetry readings can plateau misleadingly near the mid-80s to low-90s regardless of true oxygenation status.

The insidious feature for dermatology practices is the overlap between these symptoms and common complaints in the skin-disease population — fatigue and malaise in particular. Without a specific index of suspicion, early methemoglobinemia can masquerade as unrelated illness or disease progression.

Confirmation rests on a co-oximetry-measured methemoglobin level, with fractions rising above normal values indicating clinically relevant elevation. Symptoms typically track with the percentage: mild elevations may be asymptomatic, while higher fractions produce the classic cyanosis, dyspnea and neurologic sequelae.

Which clinical indicators did the study focus on?

The study's core contribution is its attempt to codify the indicators that should prompt a dermatologist to suspect the diagnosis in an outpatient on dapsone therapy. Retrospective cohort work of this kind typically evaluates combinations of:

• Patient-reported symptoms such as unexplained fatigue, dyspnea, headache or dizziness emerging after dapsone initiation or dose escalation
• Objective measures, including methemoglobin fraction on co-oximetry and changes in oxygenation parameters
• Timing relative to the dapsone regimen, including dose level and duration of exposure
• Patient factors that modify risk, such as comorbidities, interacting medications and inherited hemoglobin or enzymatic variants like G6PD deficiency

The pilot nature of the analysis signals that the authors view these indicators as hypothesis-generating. Larger prospective cohorts will be needed to validate which combination of findings carries sufficient predictive value to change routine monitoring practice.

What are the practical implications for prescribers?

For dermatologists who prescribe dapsone regularly, the study reinforces a monitoring discipline grounded in baseline and interval assessment. Standard practice already includes baseline complete blood count, liver function testing and G6PD screening where appropriate, given dapsone's parallel risk of hemolytic anemia. The methemoglobinemia data add a layer: clinicians should counsel patients on the symptom cluster and treat new dyspnea or cyanosis on dapsone as a co-oximetry-level question, not a routine complaint.

The outpatient setting is the study's defining context. Most dapsone prescribing in dermatology occurs outside hospitals, where the safety net of continuous telemetry and laboratory surveillance does not exist. Identifying which indicators can be detected in a clinic visit — through history, simple oximetry interpretation and targeted blood testing — is therefore the study's most relevant contribution to daily practice.

Where does this leave the field?

As a pilot retrospective analysis, the study establishes a clinical framework for recognizing dapsone-induced methemoglobinemia in dermatology outpatients, and its findings now await confirmation in larger, prospective cohorts before they can be translated into formal monitoring guidelines.